Sofia G. Verstraete, M.D.
Student in an Organized Health Care Education/Training Program
At a glance
- In the NPI registry since
- 2009
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Student in an Organized Health Care Education/Training Program primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $345,552 in research payments for these studies, mostly to the institutions running them.
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Eli Lilly and Company · Recruiting · NCT04844606 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to Severely Active …
Celgene Corporation - A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Eli Lilly and Company · Completed · NCT05784246 - An openlabel singlearm study to evaluate the efficacy pharmacokinetics and safety of etrasimod in adolescent subjects with moderately to severely active ulcerative colitis
Pfizer Inc. - Openlabel induction and maintenance study of oral CP690550 tofacitinib in children with moderately to severely active ulcerative colitis
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.